The Future of

Early-Stage Detection
of Infectious Diseases

20/20 is a global leader in the application of machine learning to lab tests for early cancer detection and other diseases, including the current health emergency.

Invest Now
Watch Video

Early Detection Saves Lives

Early detection of many infectious diseases through screening drastically improves survival, but there is a lack of accurate testing for a range of cancers and other diseases.

Stage 1
Stage 4
Screen Detected
>90%
Stage 1
Cancer: 5-year survival rate
First Commonly
Diagnosed
<10%
Stage 4

Detecting cancer early with machine learning, powered by real-world data

To the best of our knowledge, 20/20 is the first company to commercialize multi-cancer screening blood tests powered by AI and machine learning algorithms built with real-world outcome data from tens of thousands of previously tested individuals.

  • Screening tests and algorithms must be validated in a “pre-diagnostic” population (i.e. individuals tested before being diagnosed with cancer) to be proven reliable.
  • Our approach of “harvesting” real-world data permits rapid validation from this population with limited costs.

Headline: A.I. Powered Algorithms to Improve Cancer Detection for Multiple Cancers

Our product, OneTest™, is a multi-cancer blood test aimed at aiding in the early detection of cancer through tumor marker testing powered by machine learning algorithms built with data from tens of thousands of individuals tested before being diagnosed with cancer.

  • These proprietary algorithms combine the levels of multiple tumor biomarkers (such as CEA, AFP, CA-125, etc.) with clinical factors (e.g. age, gender, smoking history, etc.) and automatically finds “look-alikes” between the tested individuals and tens of thousands of individuals previously tested with the same biomarkers for whom cancer incidences are known.
  • Biomarker trends from repeat tests are collected, displayed, and stored on our portal since rising biomarker levels often signal an early-stage disease.

We believe that 20/20 is one of the first, if not the first, company to adopt this approach and is actively building patents and other barriers to market entry by emerging competitors.

The data used to build the 20/20 algorithms has been collected over several years and we continually acquire new data from product use worldwide.  This further improves our algorithms and we believe distances us from would-be competitors.

Everyone stands to benefit from accessible and effective cancer detection

Studies show in the United States that 1 in 2 women and 1 in 3 men will develop some form of cancer in their lifetime (source). The future is looking bleaker as well, with the number of new cases of cancer set to nearly double by the year 2050.

Chances of Developing Cancer

1 in 2
(50%)
women will develop some form of cancer in their lifetime
1 in 3
(33%)
men will develop some form of cancer in their lifetime
  • Recent studies by leading cancer geneticists at Johns Hopkins suggest that far more cancers are caused by aging than from family history, the environment, or lifestyle. This suggests that all adults, beginning in middle age, should be screened regularly for a wide array of cancers.
  • Thus the market for multi-cancer screening blood tests includes all adults worldwide roughly between the ages of 45 and 75 (the optimum ages for cancer screening.)   Currently, there are no widely used safe and affordable tests that help identify as many cancers as our OneTest at comparable price and accuracy levels

U.S Quarterly Cancer Test Volume, 2019

The Demand for OneTest™

Cancer test volume (or revenues) doubled each Quarter in 2019

Expansion To New Verticals

Fire Departments--an important market segment due to high cancer incidence and death rates--in the following states have ordered OneTest as of December 2019: Maryland, Virginia, Louisiana, Texas, and Indiana.

International Demand is Growing

Studies show in the United States that 1 in 2 women and 1 in 3 men will develop some form of cancer in their lifetime (source). The future is looking bleaker as well, with the number of new cases of cancer set to nearly double by the year 2050.

Data-Backed Results

Results of A.I. Algorithm Improvements: OneTest correctly classified this individual as increased probability of Gastro- Intestinal (GI) cancer. Standard cancer marker tests showed no abnormal levels.

  • Gender: Male
    Age: 60
    Tumor Markers Above Standard Cut- Offs: None
    Subsequent Diagnosis: Liver Cancer Stage I

Exponentially Improved Sensitivity

OneTest™ can significantly increase cancer detection rates by identifying important patterns in tumor maker results, which might fall below the standard manucaturers cutoff values.

OneTest A.I. Algorithms improve Cancer Marker Tests Real World Example

Our Team is on a Mission to Reduce Cancer Mortality

Jonathan Cohen, MS JD.
President & CEO
  • Co-inventor of 20/20’s successful OneTest and BioCheck® products
  • Led financing rounds totalling over $20 million
  • Forged strategic alliances with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, and Ping An Ventures
  • Served a Patent and General Counsel for two publicly traded companies with tree decades of experience as a patent attorney
  • Master of Science in Biotechnology from Johns Hopkins University and a law degree from the American University.
John Compton, Ph.D.
Board Chair
  • Served as Scientific Director and Co-President of GeneDx Inc
    • Operating assets of which were acquired by BioReference
    • Laboratories (now part of Opko) in September 2006.
  • GeneDx is a world leader in genomics with an expertise in rare and ultra-rare genetic disorders as well as one of the broadest menus of sequencing services available among commercial laboratories.
  • 25 years experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation and has authored more than 60 publications in the field.
    • B.S. degrees in Physics and Biology from MI
      • Ph.D. from the University of California, Berkeley in Biophysics
        • Post-doctoral training in protein-DNA interactions at the Baylor College of Medicine.
          Ted Driscoll, Ph.D.
          Director
          • Harvard, Stanford
          • Started five companies that pioneered digital imaging. (Patents include iPhone digital fingerprint recognition, first MRI scanner, 360-degree imaging that became Google Street View)
          • Former VC with Claremont Creek
          • Pioneer in promoting CLIA Lab approach as FDA alternative

          China’s Ping An, likely the world’s largest Healthcare AI company with nearly 300 million users of its Good Doctor mobile diagnostic app, is a large investor and Board member in 20/20  and has begun in late 2019 to help implement our China strategy.

          Strategic Partnership Gives Access to Millions

          China’s Ping An, likely the world’s largest Healthcare AI company with nearly 300 million users of its Good Doctor mobile diagnostic app, is a large investor and Board member in 20/20  and has begun in late 2019 to help implement our China strategy.

          Innovative Business Model

          A cloud accessible tool to improve the accuracy of tumor marker blood tests.

          Current market focus is occupational health (professions at risk for cancers)
          Direct-to-consumer marketing using social media demonstrated to be cost-effective

          Invest in Early-Stage Cancer Detection Medicine

          Invest Now